Pancreatic Cancer Research

ResearcherUniversity of California San DiegoActive in the last 2 years

Takashi Murakami

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9429-5705; OpenAlex author ID A5060520190. Sources: OpenAlex.

Their work

Papers
28 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2014: 5 papers · 2015: 2 papers · 2016: none · 2017: 6 papers · 2018: 5 papers · 2019: 4 papers · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 28

  1. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  2. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  3. Neoadjuvant Chemoradiotherapy Enhances Tumor PD-L1 Expression in Pancreatic Cancer. First author DOI 10.21873/anticanres.17554↗
  4. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemorad… Co-author DOI 10.1002/jhbp.883↗
  5. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy. Co-author DOI 10.1007/s00268-020-05503-4↗
  6. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Co-author DOI 10.1038/s41416-020-0782-1↗
  7. Role of the tumor microenvironment in pancreatic cancer. Co-author DOI 10.1002/ags3.12225↗
  8. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Fo… First author DOI 10.1007/s00268-019-05159-9↗
  9. MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negativ… Co-author DOI 10.1245/s10434-019-07793-y↗
  10. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative R… Co-author DOI 10.21873/anticanres.13615↗
  11. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Can… Co-author DOI 10.1002/jcb.26224↗
  12. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Co-author DOI 10.1016/j.tice.2018.05.003↗
  13. Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore. First author DOI 10.1245/s10434-018-6344-6↗
  14. Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model. Co-author DOI 10.18632/oncotarget.26484↗
  15. Fluorescence-guided Surgery with Splenic Preservation Prevents Tumor Recurrence in an Orthotopic Nude-mouse Model of Human Pancreatic Cancer. Co-author DOI 10.21873/anticanres.12270↗
  16. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility co… Co-author DOI 10.1002/jso.24681↗
  17. MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy. Co-author DOI 10.1016/j.jss.2017.07.003↗
  18. Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer or… Co-author DOI 10.1080/15384101.2017.1315489↗
  19. Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-16-0670↗
  20. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). Co-author DOI 10.18632/oncotarget.17667↗
  21. Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model. First author DOI 10.18632/oncotarget.21331↗
  22. Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model r… Co-author DOI 10.1016/j.pan.2015.02.008↗
  23. Design and Function of Engineered Protein Nanocages as a Drug Delivery System for Targeting Pancreatic Cancer Cells via Neuropilin-1. Co-author DOI 10.1021/mp5007129↗
  24. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1245/s10434-013-3390-y↗
  25. Fluorescence-guided surgery in combination with UVC irradiation cures metastatic human pancreatic cancer in orthotopic mouse models. Co-author DOI 10.1371/journal.pone.0099977↗
  26. The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid. Co-author DOI 10.1371/journal.pone.0103382↗
  27. Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combinati… Co-author DOI 10.1371/journal.pone.0114310↗
  28. Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenogra… Co-author DOI 10.18632/oncotarget.2641↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Itaru Endo · 19 shared papers, 2014–2026 · strength 1.83
  2. Yasuhiro Yabushita · 7 shared papers, 2019–2026 · strength 1.11
  3. Yukihiko Hiroshima · 12 shared papers, 2014–2025 · strength 0.94
  4. Robert M. Hoffman · 15 shared papers, 2014–2019 · strength 0.93
  5. Kentaro Miyake · 9 shared papers, 2017–2025 · strength 0.86
  6. Michael Bouvet · 14 shared papers, 2014–2018 · strength 0.82
  7. Yuki Homma · 8 shared papers, 2014–2021 · strength 0.66
  8. Michiaki Unno · 4 shared papers, 2017–2026 · strength 0.58
  9. Yoshiaki Murakami · 2 shared papers, 2025–2026 · strength 0.44
  10. Sohei Satoi · 2 shared papers, 2025–2026 · strength 0.44
  11. Shuji Isaji · 2 shared papers, 2025–2026 · strength 0.44
  12. Suguru Yamada · 2 shared papers, 2025–2026 · strength 0.44
  13. Masanori Oshi · 2 shared papers, 2025–2026 · strength 0.44
  14. Masayuki Sho · 2 shared papers, 2025–2026 · strength 0.44
  15. Hiroki Yamaue · 2 shared papers, 2025–2026 · strength 0.44
  16. Satoshi Hirano · 2 shared papers, 2025–2026 · strength 0.44
  17. Goro Honda · 2 shared papers, 2025–2026 · strength 0.44
  18. Masayuki Ohtsuka · 2 shared papers, 2025–2026 · strength 0.44
  19. Ho Kyoung Hwang · 6 shared papers, 2017–2018 · strength 0.42
  20. Thinzar Min Lwin · 5 shared papers, 2017–2018 · strength 0.35
  21. Nobuhiro Tsuchiya · 3 shared papers, 2019–2020 · strength 0.33
  22. Yasushi Ichikawa · 7 shared papers, 2014–2018 · strength 0.31
  23. Kanechika Den · 2 shared papers, 2017–2025 · strength 0.30
  24. Hirokazu Kubo · 2 shared papers, 2019 · strength 0.19
  25. Ali A. Maawy · 5 shared papers, 2014–2015 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.